Polyserositis as a Unique Presentation of Isolated Myeloid Sarcoma: A Case Report

Asawa, Palash; Vusqa, Urwat Til; Vashistha, Kirtivardhan; Din, Mian Tanveer Ud; Karna, Rahul; Chen, Feifan; Dutton, Nina; Samhouri, Yazan; Fazal, Salman

doi:10.21873/anticanres.15846

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myeloid sarcoma is a rare tumor formed by extramedullary accumulation of myeloblasts or immature myeloid cells 1. It can occur at any site of the body, including soft tissues, bone, lymph nodes, and skin [2][3][4]. Previous studies have reported the use of 18 F-FDG PET/CT in staging and response assessment in myeloid sarcoma.5,6 68 Ga-DOTA-FAPI-04 is a novel tumor tracer based on fibroblast-activation protein.…”

mentioning

confidence: 99%

See 1 more Smart Citation

18F-FDG PET/CT and 68Ga-DOTA-FAPI-04 PET/CT Findings of Myeloid Sarcoma

et al. 2022

View full text Add to dashboard Cite

A 28-year-old woman presented with a 2-month history of swelling and pain in the chest wall. An irregular soft tissue mass in the chest wall and mediastinum was showed on chest CT. 18F-FDG PET/CT revealed obvious FDG uptake in the mass. Subsequently, the patient was participated in a 68Ga-DOTA-FAPI-04 PET/CT tumor clinical trial. 68Ga-DOTA-FAPI-04 PET/CT also showed elevated tracer uptake in the mass. Biopsy of the mass confirmed a diagnosis of myeloid sarcoma.

show abstract

mentioning

confidence: 99%

“…Myeloid sarcoma is a rare tumor formed by extramedullary accumulation of myeloblasts or immature myeloid cells 1 . It can occur at any site of the body, including soft tissues, bone, lymph nodes, and skin 2–4 . Previous studies have reported the use of 18 F-FDG PET/CT in staging and response assessment in myeloid sarcoma 5,6 .…”

mentioning

confidence: 99%

18F-FDG PET/CT and 68Ga-DOTA-FAPI-04 PET/CT Findings of Myeloid Sarcoma

et al. 2022

View full text Add to dashboard Cite

show abstract

Venetoclax plus Azacitidine as the Induction Therapy for Cardiac Myeloid Sarcoma - A Case Report with Review of Literature

Lin

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Cardiac myeloid sarcoma is a rare extramedullary tumor of acute myeloid leukemia, and its optimal treatment strategy has not been established such as avoiding conventional anthracycline-containing induction chemotherapy because of unwanted cardiotoxicity. Recently, venetoclax combined with azacitidine was approved for newly diagnosed acute myeloid leukemia patients who are not unsuitable for intensive chemotherapy. To the best of our knowledge, there have been no reported cases of cardiac myeloid sarcoma treated with this combination regimen.Case presentation A 63-year-old man presented with progressive dyspnea on exertion. Echocardiography showed a massive pericardial effusion. Computed tomography of the chest revealed an infiltrative mass at the right atrioventricular groove with thickened epicardium and pericardium, and multifocal lymphadenopathy. Initially, he was suspected to have IgG4-related disease and Erdheim-Chester disease, based on elevated serum lgG4 levels and histopathological findings of axillary lymph node and endomyocardial biopsy. Despite treatment, his left ventricular systolic dysfunction rapidly deteriorated. Peripheral blood blasts were unexpectedly observed later, and subsequent bone marrow examination confirmed acute myeloid leukemia. Retrospective review of the endomyocardial biopsy specimen verified the diagnosis of cardiac myeloid sarcoma. To minimize the risk of chemotherapy-induced cardiotoxicity, we chose venetoclax plus azacitidine as induction therapy, followed by high-dose cytarabine consolidation and allogeneic hematopoietic stem cell transplant, which lead to a complete remission.Conclusions Although extremely rare, cardiac myeloid sarcoma can cause fulminant heart failure and should be included in the differential diagnosis of cardiac tumors, even without a prior history of hematologic disorders. Our report demonstrates for the first time that the combination of venetoclax and azacitidine is an effective and safe induction therapy for cardiac myeloid sarcoma.

show abstract

Myeloid Sarcoma as a Presentation of Acute Myeloid Leukemia and Blastic Phase in the Course of Chronic Myeloid Leukemia: A Case Report and Literature Review

Giordano

Sawicki²,

Pilch

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Myeloid sarcoma (MS), also known as granulocytic sarcoma or chloroma, is a rare disease entity characterized by the emergence of an extramedullary tumor, which may be antecedent, coexisting, or manifest secondarily to an ongoing malignancy of lymphoid origin. Owing to its low prevalence, scientific reports addressing this matter comprise mainly retrospective studies with a limited number of participants, rather low-quality research, and only few case reports. Despite MS’s rarity, the need for enhancing their diagnostic tools and refinement of their therapeutic regimens is broadly recognized among physicians. Case summary: In this case series, we present the clinical histories of two patients diagnosed with MS. The former (Case 1) exhibited MS of the sternum alongside chronic myeloid leukemia (CML), while in case of the latter (Case 2) MS presented as the initial manifestation of a current acute myeloid leukemia (AML). Treatment for both patients included chemotherapy (CHTH) and radiation (RT); however, patient 1 with CML died due to cardiorespiratory insufficiency secondary to an infection, while patient 2 is in clinical remission (CR) for 16 months since their MS diagnosis. Furthermore, a comprehensive analysis of previously reported cases was conducted which incorporated MS in patients with AML and CML. Conclusion: The objective of this report was to emphasize the heterogeneity among the clinical manifestations of MS, to underline the relevance of the histopathological and molecular diagnostic tools in opting for the appropriate therapy, and that, in spite of it occurring rather uncommonly, physicians should think of MS in the presence of pathological masses in patients under risk of hematological malignancies.

show abstract

Polyserositis as a Unique Presentation of Isolated Myeloid Sarcoma: A Case Report

Cited by 3 publications

References 0 publications

18F-FDG PET/CT and 68Ga-DOTA-FAPI-04 PET/CT Findings of Myeloid Sarcoma

18F-FDG PET/CT and 68Ga-DOTA-FAPI-04 PET/CT Findings of Myeloid Sarcoma

Venetoclax plus Azacitidine as the Induction Therapy for Cardiac Myeloid Sarcoma - A Case Report with Review of Literature

Myeloid Sarcoma as a Presentation of Acute Myeloid Leukemia and Blastic Phase in the Course of Chronic Myeloid Leukemia: A Case Report and Literature Review

Contact Info

Product

Resources

About